RFK Jr. Pushes FDA to Reopen Access to 7 Banned Peptides After 2023 Crackdown
The FDA is moving to reconsider restrictions on a group of unapproved peptide drugs backed by Health Secretary Robert F. Kennedy Jr., setting up a high-stakes policy shift in U.S. healthcare.
The agency confirmed it will convene an outside advisory panel in July to review whether seven peptides should be removed from a restricted list, reopening access through compounding pharmacies.
According to the Associated Press, the substances, such as BPC-157 and TB-500, were limited in 2023 after regulators warned they posed safety risks and lacked sufficient human testing.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →
The review comes as Kennedy pushes a broader deregulation agenda tied to his “Make America Healthy Again” movement, which emphasizes alternative therapies and expanded access.
“I’m a big fan of peptides,” Kennedy said, citing personal use in a podcast interview.
The shift highlights a growing divide in federal health policy, where supporters argue loosening restrictions could bring oversight to a booming gray market, while critics warn it risks bypassing decades of FDA safety standards.
The July meeting is expected to guide future rule-making, with potential changes affecting compounding pharmacies, supplement markets, and clinical research pathways nationwide.
For now, the policy remains under review, with final decisions likely months away.
Download a FREE Pocket Constitution NOW →
